MediVera Compounding Pharmacy lists NAD+ injection as a preparation made following a licensed clinician’s prescription. Its public page describes the formulation, possible administration routes, storage, and ways a provider can submit an order. Those details make it a pharmacy-supplier resource rather than a complete online-treatment subscription.
We checked the product page on September 19, 2026. We did not order medication, audit the pharmacy, or test its product. This review helps distinguish the information in a catalog from the instructions and financial terms that must accompany an individual prescription.
MediVera’s catalog is useful for identifying the preparation. Have the pharmacy confirm the actual label and usable dates, and compare the prescribing service separately.
The listed formulation is a starting point
The MediVera NAD+ page lists a 100 mg/mL preparation in a 10 mL vial. It describes subcutaneous or intramuscular administration according to the prescriber’s directions. Neither the vial size nor the route examples establish the dose or schedule appropriate for a particular patient.
Ask the pharmacist to confirm that the listing matches the actual product being dispensed. Our label-reading guide explains which quantities and markings need to be understood. If a clinician selects a different strength or formulation, the instructions should be reviewed for that preparation rather than borrowed from a generic page.
The pharmacy and prescriber have different jobs
MediVera describes provider ordering through electronic records, fax, phone, and a portal. Those pathways explain how a prescription can reach the pharmacy; they do not replace a medical evaluation. A patient needs a clinician to assess the reason for treatment and a pharmacy to address the dispensed preparation.
Before proceeding, identify who is responsible for follow-up and who answers product questions. The consultation checklist helps separate clinical decisions from delivery and billing tasks. Knowing the pharmacy name is helpful, but it does not tell you what care a telehealth service or clinic has agreed to provide.
Read the usable-period wording carefully
MediVera’s FAQ gives a general statement about an approximately thirty-day beyond-use period from dispensing and describes refrigerated storage. That is not permission to assign the same date to every vial. Ask the pharmacy for the dates and handling instructions that apply to the preparation actually supplied to you.
If a service sells a multi-month plan, ask how its shipment schedule fits those dates. A longer payment period does not establish that one opened vial remains usable throughout it. Also ask who assesses a delayed delivery or temperature excursion; a review article cannot decide whether a particular parcel should be used.
A supplier listing does not establish an all-in price
The product page does not provide a complete treatment quote including evaluation, medication, supplies, and follow-up. Ask the prescribing service and pharmacy which charges each collects. If insurance or a benefits account is discussed, obtain confirmation for the actual prescription rather than assuming coverage from a general payment statement.
Our NAD+ cost guide explains why the pharmacy charge and the service total can differ. Two clinics using the same supplier may offer different amounts of support or different billing structures. Compare what is included, the supplied quantity, and the payment schedule before deciding whether one is less expensive.
Quality statements and clinical evidence are separate
MediVera describes its preparation standards and explicitly acknowledges the compounded product’s lack of FDA approval. A statement about manufacturing practices does not demonstrate that the medication will improve a particular symptom. Likewise, a wellness claim does not independently verify how a specific batch was prepared or handled.
The pharmacy-checking guide helps organize facility questions, while the evidence review addresses the medical claims. Ask the prescriber what outcome would justify treatment and when it should be reassessed. Those questions remain relevant even when a catalog is detailed and easy to read.
Compare the actual preparations and care arrangements
Read Hallandale Pharmacy for another premixed injection listing and Wells Pharmacy Network for a lyophilized product with different preparation questions. Belmar Pharma Solutions illustrates a catalog covering several routes. These are supplier comparisons, not claims that the products are interchangeable.
Our CoreAge Rx review covers the featured commercial partner at the service level. This MediVera review does not establish which online brands use the pharmacy for a particular patient. Its value is a clearer understanding of the product information, responsibilities, and dates to verify when MediVera is named on your prescription.
Follow the source
References & further reading
- MediVera — NAD+ injection information
Checked September 19, 2026. Catalog formulation and general usable-date wording; the actual dispensed label controls product-specific instructions.
- FDA — compounding questions and answers
Compounded drugs are not FDA-approved or reviewed before marketing for safety, effectiveness, or quality.
- FDA — ingredients suitable for sterile compounding
Reports NAD+ injectable adverse events and ingredient-quality concerns.
- Grant et al. (2019) — human NAD+ infusion pilot
Small IV metabolism study; does not establish benefits of home injections.